7 results on '"Thomas Kolben"'
Search Results
2. Permixon®, hexane-extracted Serenoa repens, inhibits human prostate and bladder smooth muscle contraction and exerts growth-related functions in human prostate stromal cells
- Author
-
Alexander, Tamalunas, Amin, Wendt, Florian, Springer, Victor, Vigodski, Anna, Ciotkowska, Beata, Rutz, Ruixiao, Wang, Ru, Huang, Yuhan, Liu, Heiko, Schulz, Stephan, Ledderose, Thomas, Kolben, Giuseppe, Magistro, Christian G, Stief, and Martin, Hennenberg
- Subjects
Male ,Endothelin-1 ,Phalloidine ,Plant Extracts ,Urinary Bladder ,Prostate ,Prostatic Hyperplasia ,Thromboxanes ,Muscle, Smooth ,General Medicine ,Actins ,Sincalide ,General Biochemistry, Genetics and Molecular Biology ,Adrenergic Agents ,Serenoa ,Hexanes ,Humans ,Stromal Cells ,General Pharmacology, Toxicology and Pharmaceutics ,Methacholine Chloride ,Muscle Contraction - Abstract
Recently, the European Association of Urology recommended hexane-extracted fruit of Serenoa repens (HESr) in their guidelines on management of non-neurogenic male lower urinary tracts symptoms (LUTS). Despite previously lacking recommendations, Permixon® is the most investigated HESr in clinical trials, where it proved effective for male LUTS. In contrast, underlying mechanisms were rarely addressed and are only marginally understood. We therefore investigated effects of Permixon® on human prostate and detrusor smooth muscle contraction and on growth-related functions in prostate stromal cells.Permixon® capsules were dissolved using n-hexane. Contractions of human prostate and detrusor tissues were induced in organ bath. Proliferation (EdU assay), growth (colony formation), apoptosis and cell death (flow cytometry), viability (CCK-8) and actin organization (phalloidin staining) were studied in cultured human prostate stromal cells (WPMY-1).Permixon® inhibited αOur results provide a novel basis that allows, for the first time, to fully explain the ubiquitous beneficial effects of HESr in clinical trials. HESr may inhibit at least neurogenic, α
- Published
- 2022
3. Gestational diabetes mellitus and COVID-19: results from the COVID-19–Related Obstetric and Neonatal Outcome Study (CRONOS)
- Author
-
Helmut J. Kleinwechter, Katharina S. Weber, Nina Mingers, Babett Ramsauer, Ute M. Schaefer-Graf, Tanja Groten, Bettina Kuschel, Clara Backes, Constanze Banz-Jansen, Martin A. Berghaeuser, Irene A. Brotsack, Iris Dressler-Steinbach, Charlotte Engelbrecht, Sarah Engler-Hauschild, Teresa-Mira Gruber, Vanessa Hepp, Elsa Hollatz-Galuschki, Antonella Iannaccone, Anja Jebens, Constantin S. von Kaisenberg, Lisa Kaup, Corinna Keil, Carolin Kladt, Thomas Kolben, Katrina Kraft, Mirjam Kunze, Julia Lastinger, Katharina Luedemann, Jula Manz, Christine A. Morfeld, Olaf Parchmann, Lena Pfaff, Kristin Reinhardt, Anne Runkel, Markus Schmidt, Marina Sourouni, Johanna Stelbrink, Johannes Stubert, Florian M. Stumpfe, Anna Treptow, Mario Rüdiger, and Ulrich Pecks
- Subjects
Adult ,SARS-CoV-2 ,Medizin ,Infant, Newborn ,Insulins ,Pregnancy Outcome ,COVID-19 ,Obstetrics and Gynecology ,Overweight ,Diabetes, Gestational ,COVID-19 Testing ,Pregnancy ,Outcome Assessment, Health Care ,Humans ,Female ,Obesity - Abstract
Background: Gestational diabetes mellitus is one of the most frequent pregnancy complications with a global prevalence of 13.4% in 2021. Pregnant women with COVID-19 and gestational diabetes mellitus are 3.3 times more likely to be admitted to an intensive care unit than women without gestational diabetes mellitus. Data on the association of gestational diabetes mellitus with maternal and neonatal pregnancy outcomes in pregnant women with SARS-CoV-2 infection are lacking. Objective: This study aimed to investigate whether gestational diabetes mellitus is an independent risk factor for adverse maternal and fetal and neonatal outcomes in pregnant women with COVID-19. Study Design: The COVID-19-Related Obstetric and Neonatal Outcome Study is a registry-based multicentric prospective observational study from Germany and Linz, Austria. Pregnant women with clinically confirmed COVID-19 were enrolled between April 3, 2020, and August 24, 2021, at any stage of pregnancy. Obstetricians and neonatologists of 115 hospitals actively provided data to the COVID-19-Related Obstetric and Neonatal Outcome Study. For collecting data, a cloud-based electronic data platform was developed. Women and neonates were observed until hospital discharge. Information on demographic characteristics, comorbidities, medical history, COVID-19–associated symptoms and treatments, pregnancy, and birth outcomes were entered by the local sites. Information on the periconceptional body mass index was collected. A primary combined maternal endpoint was defined as (1) admission to an intensive care unit (including maternal mortality), (2) viral pneumonia, and/or (3) oxygen supplementation. A primary combined fetal and neonatal endpoint was defined as (1) stillbirth at ≥24 0/7 weeks of gestation, (2) neonatal death ≤7 days after delivery, and/or (3) transfer to a neonatal intensive care unit. Multivariable logistic regression analysis was performed to evaluate the modulating effect of gestational diabetes mellitus on the defined endpoints. Results: Of the 1490 women with COVID-19 (mean age, 31.0±5.2 years; 40.7% nulliparous), 140 (9.4%) were diagnosed with gestational diabetes mellitus; of these, 42.9% were treated with insulin. Overall, gestational diabetes mellitus was not associated with an adverse maternal outcome (odds ratio, 1.50; 95% confidence interval, 0.88–2.57). However, in women who were overweight or obese, gestational diabetes mellitus was independently associated with the primary maternal outcome (adjusted odds ratio, 2.69; 95% confidence interval, 1.43–5.07). Women who were overweight or obese with gestational diabetes mellitus requiring insulin treatment were found to have an increased risk of a severe course of COVID-19 (adjusted odds ratio, 3.05; 95% confidence interval, 1.38–6.73). Adverse maternal outcomes were more common when COVID-19 was diagnosed with or shortly after gestational diabetes mellitus diagnosis than COVID-19 diagnosis before gestational diabetes mellitus diagnosis (19.6% vs 5.6%; P
- Published
- 2022
4. Effects of SARS-CoV-2 on prenatal lung growth assessed by fetal MRI
- Author
-
Sophia Stoecklein, Vanessa Koliogiannis, Tobias Prester, Thomas Kolben, Magdalena Jegen, Christoph Hübener, Uwe Hasbargen, Andreas Flemmer, Olaf Dietrich, Regina Schinner, Julien Dinkel, Nicola Fink, Maximilian Muenchhoff, Susan Hintz, Maria Delius, Sven Mahner, Jens Ricke, and Anne Hilgendorff
- Subjects
Pulmonary and Respiratory Medicine ,Pregnancy ,SARS-CoV-2 ,COVID-19 ,Humans ,Female ,Prenatal Care ,Pregnancy Complications, Infectious ,Lung ,Magnetic Resonance Imaging - Published
- 2022
5. The role of Interleukin-18 in recurrent early pregnancy loss
- Author
-
Zhi Ma, Achim Wöckel, Elisa Schmoeckel, Udo Jeschke, Sven Mahner, Saskia-Laureen Herbert, Theresa Vilsmaier, Sanja Löb, Beate Ochmann, Thomas Kolben, and Christina Kuhn
- Subjects
Adult ,Abortion, Habitual ,Placenta ,Early Pregnancy Loss ,medicine.medical_treatment ,Immunology ,Andrology ,Young Adult ,Pregnancy ,Recurrent miscarriage ,Decidua ,medicine ,Humans ,Immunology and Allergy ,Fetus ,business.industry ,Interleukin-18 ,Obstetrics and Gynecology ,Gestational age ,medicine.disease ,Up-Regulation ,Pregnancy Trimester, First ,medicine.anatomical_structure ,Cytokine ,Reproductive Medicine ,Female ,Interleukin 18 ,business ,Biomarkers - Abstract
Background A successful pregnancy is a unique and complex immunological state. Cytokines seem to be crucial for the implementation of a tolerogenic environment at the feto-maternal interphase towards the semi-allogenic fetus. Importantly, the switch from a Th1- to a Th2 cytokine profile might play a key role. Interestingly, Interleukin-18 (IL-18) can induce either Th1 or Th2 immune response depending on the local cytokine environment. Therefore, this study investigates the expression of IL-18 in early pregnancy loss. Patients and Methods The TaqMan® Human Cytokine Network Array was carried out with placental tissue of patients with healthy pregnancies (n = 15) and recurrent miscarriage (n = 15) in order to investigate differences in IL-18 mRNA expression. Immunohistochemical staining was applied to examine the IL-18 protein expression in the syncytiotrophoblast and decidua of healthy pregnancies (n = 15), spontaneous (n = 12) and recurrent miscarriage (n = 9). The characterization of IL-18 expressing cells in the decidua was evaluated by double-immunofluorescence. Correlation analysis between IL-18 protein expression and clinical data of the study population was performed via spearman correlation coefficient. Results Gene expression analysis revealed a 4,9-times higher expression of IL-18 in recurrent miscarriage patients. IL-18 protein expression was significantly upregulated only in the decidua in the recurrent miscarriage group (p = 0.031). We did not observe significant changes of IL-18 protein expression in spontaneous miscarriage specimens when compared to healthy controls (p = 0.172). Double-immunofluorescence identified decidual stroma cells as IL-18 expressing cells. Correlation analysis showed a significant negative correlation of IL-18 protein expression and gestational age in healthy controls (r = -,745, p = 0.034). Also, a positive correlation of IL-18 and maternal age was observed in patients suffering from recurrent pregnancy loss (r =, 894, p = 0.041). Conclusion Our results indicate that IL-18 expression might be necessary in early gestation but requires a tight regulation for a successful ongoing pregnancy. In the present study we observed that a significant upregulation of IL-18 in the decidua was restricted to patients with recurrent miscarriage and therefore might be interesting as a diagnostic marker. Further studies need to evaluate the exact pathophysiological mechanisms.
- Published
- 2021
6. Sex-specific epigenetic gene activation profiles are differentially modulated in human placentas affected by intrauterine growth restriction
- Author
-
Viola Obermeier, Thomas Kolben, Maria Emilia Solano, Simone Hofmann, Julia Messner, Sven Mahner, Magdalena Jegen, Christina Kuhn, Petra C. Arck, Stefan Hutter, Udo Jeschke, S Meister, Doris Mayr, and S Beyer
- Subjects
Adult ,Male ,0301 basic medicine ,Placenta ,Prednisolone ,Immunology ,Intrauterine growth restriction ,Syncytiotrophoblasts ,Biology ,Cell Line ,Epigenesis, Genetic ,Histones ,Andrology ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Gene expression ,medicine ,Humans ,Immunology and Allergy ,Epigenetics ,reproductive and urinary physiology ,Regulation of gene expression ,Fetus ,Fetal Growth Retardation ,030219 obstetrics & reproductive medicine ,Obstetrics and Gynecology ,medicine.disease ,Trophoblasts ,030104 developmental biology ,Histone ,Reproductive Medicine ,embryonic structures ,biology.protein ,Regression Analysis ,H3K4me3 ,Female ,Sex - Abstract
Background The purpose of this study was to investigate the sex specific expression of histone protein modifications responsible for rapid gene expression in IUGR placentas. Patients and Methods We screened for fetal sex-specific expression of the histone proteins H3K4me3 and H3K9ac in 23 IUGR and 40 control placentas via immunohistochemistry. The trophoblast-like cell line BeWo was used in order to analyze a potential effect of stimulation with prednisolone on H3K4me3 and H3K9ac in vitro. Calculating regression models with additional adjustment for potential confounders were used. Results A significantly decreased level of H3K4me3 was detectable in female syncytiotrophoblasts, whereas H3K9ac was reduced predominantly in male extravillous throphoblast (EVT). No association to the gestational age existed. Conclusion Our data showed a reduced expression of the histone proteins H3K4me3 (female) and H3K9ac (male) in IUGR, furthermore elevated cortisol levels may lead to a sex-specific down-regulation of histone proteins in IUGR placentas.
- Published
- 2020
7. BP52 IS THERE A DIFFERENT TREATMENT RESPONSE BETWEEN VISCERAL AND NON-VISCERAL METASTATIC BREAST CANCER: A SYSTEMATIC LITERATURE REVIEW OF REGISTRATION TRIALS
- Author
-
Caroline Gehring, Alexander König, Nadia Harbeck, Rachel Würstlein, Maximilian Bardenhewer, and Thomas Kolben
- Subjects
Oncology ,Treatment response ,medicine.medical_specialty ,Systematic review ,business.industry ,Internal medicine ,medicine ,Surgery ,General Medicine ,medicine.disease ,business ,Metastatic breast cancer - Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.